Pembrolizumab (pembro) in microsatellite instability-high (MSI-H) advanced gastric/gastroesophageal junction (G/GEJ) cancer by line of therapy.

Joseph Chao,Charles S. Fuchs,Kohei Shitara,Josep Tabernero,Kei Muro,Eric Van Cutsem,Yung-Jue Bang,Ferdinando De Vita,Greg A. Landers,Chia-Jui Yen,Ian Chau,Anneli Elme,Jeeyun Lee,Mustafa Ozguroglu,Daniel V.T. Catenacci,X. Li,Chie-Schin Shih,Sukrut Shah,Pooja Bhagia,Zev A. Wainberg

Pembrolizumab (pembro) in microsatellite instability-high (MSI-H) advanced gastric/gastroesophageal junction (G/GEJ) cancer by line of therapy.

2020

430Background: Pembro has demonstrated promising antitumor activity in patients (pts) with advanced G/GEJ cancer with PD-L1 CPS ≥1 and CPS ≥10 irrespective of MSI-H status. Here, we examine the ant...

Keywords:

Cancer
Pembrolizumab
Gastroesophageal Junction
Internal medicine
Microsatellite instability
Medicine
Oncology
Pathology
line of therapy
antitumor activity
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations